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Abstract: West Nile virus (WNV) strains may differ significantly in neuroinvasiveness in vertebrate
hosts. In contrast to genetic lineage 1 WNVs, molecular determinants of pathogenic lineage 2 strains
have not been experimentally confirmed so far. A full-length infectious clone of a neurovirulent WNV
lineage 2 strain (578/10; Central Europe) was generated and amino acid substitutions that have been
shown to attenuate lineage 1 WNVs were introduced into the nonstructural proteins (NS1 (P250L),
NS2A (A30P), NS3 (P249H) NS4B (P38G, C102S, E249G)). The mouse neuroinvasive phenotype of
each mutant virus was examined following intraperitoneal inoculation of C57BL/6 mice. Only the
NS1-P250L mutation was associated with a significant attenuation of virulence in mice compared to
the wild-type. Multiplication kinetics in cell culture revealed significantly lower infectious virus titres
for the NS1 mutant compared to the wild-type, as well as significantly lower amounts of positive and
negative stranded RNA.
Keywords: West Nile virus; lineage 2; virulence markers; infectious clone
1. Introduction
West Nile virus (WNV) is one of the most widely distributed members of the genus Flavivirus
within the family Flaviviridae. The virus can cause general, febrile and severe encephalitic disease in
humans and a number of animal species. It possesses a capped and non-polyadenylated positive-sense,
single-stranded RNA genome, approximately 11 kb in length, which contains a single open reading
frame (ORF) encoding a polyprotein precursor that is co- and post-translationally processed by viral
and host cell proteases to three structural proteins (capsid protein C, pre-membrane protein prM/M,
envelope protein E) and seven non-structural (NS) proteins (glycoprotein NS1, NS2A, protease cofactor
NS2B, protease and helicase NS3, NS4A, NS4B and polymerase NS5).
Viruses 2016, 8, 49; doi:10.3390/v8020049 www.mdpi.com/journal/viruses
Viruses 2016, 8, 49 2 of 20
WNV strains have been divided into at least eight distinct genetic lineages [1–3]. The first WNV
strain, isolated in Uganda in 1937 [4], belongs to lineage 2 and this lineage has been confined to
sub-Saharan Africa and Madagascar [5]. Until the early 1990s, WNV infections beyond Africa were
caused by lineage 1 WNV strains that caused mainly mild clinical symptoms with sporadic encephalitis
in humans. Lineage 1 WNV as the causative agent of lethal encephalitis was reported in 1994, in
Algeria, followed by a high number of neuroinvasive cases in Romania, in 1996, and more frequent
encephalitis cases in several other Eastern and Western European countries [6]. Moreover, in 1999,
WNV emerged in the continental United States and rapidly spread throughout North America and
also into South America, causing increased mortality among humans and animals as well [7–9].
Lineage 2 strains did not appear to be as pathogenic as lineage 1 isolates, as they generally caused
no deaths, and only mild clinical signs of infection [10]. The first proven case of a lineage 2 virus
infection with fatal outcome outside of Africa was detected in a goshawk (Accipiter gentilis) in Hungary,
in 2004 [11,12]. This exotic WNV lineage 2 strain caused subsequent infections, illnesses and deaths
in wild birds, horses and humans [11–13], and rapidly spread to Austria [14–16], Greece [17,18] and
Italy [19,20]. Based on phylogenetic reconstruction, lineage 2 viruses isolated in Russia [21,22] and
Romania [23] cluster together, but are distinct from the Hungarian strain [16].
Several studies have aimed at identifying the molecular markers of virulence in lineage 1 WNV
strains [24–27]. A number of lineage 1 viruses of moderate virulence in mice and exhibiting inefficient
growth in cell culture have been identified so far [28]. Reverse genetic systems were established to
investigate nucleotide and amino acid alterations in the WNV lineage 1 genome that led to decreased
neurovirulence and neuroinvasiveness in mice [29,30]. Mutations in the NS protein genes, such as
NS1 [31], NS2A [24,26,32], NS3 [33], NS4B [30,34–36] and NS5 [34] ,were found to be associated with
the attenuation of these viruses.
In contrast to lineage 1 viruses, molecular determinants of pathogenic WNV lineage 2 strains
have not been confirmed experimentally. Virulence markers have only been identified in silico by
analyzing and comparing full genome sequences of highly or less neuroinvasive lineage 2 strains [37],
or by comparing those that have emerged and increased in virulence over time (1937-2011) [38]. The
aim of the present study was to investigate the in vitro (in cell culture) and in vivo (in a mouse model)
effects of selected nucleotide substitutions of the NS protein coding genes, known to be attenuating for
lineage 1, in a neurovirulent WNV lineage 2 strain (578/10) isolated in Central Europe with the help of
reverse genetic methods and site-specific mutagenesis.
2. Materials and Methods
2.1. Cells and Viruses
Transfection was carried out on baby hamster kidney 21 (BHK-21) cells (ATCC®: CCL-10TM)
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 5% foetal bovine serum
(FBS). Virus stocks were propagated and titrated on Vero E6 cells (ATCC®: CRL-1586TM) cultured in
DMEM supplemented with 0.75% sodium bicarbonate, 10 mM hepes buffer and 10% FBS. All media
was supplemented with antibiotics (100 U penicillin, 100 µg/mL streptomycin) and 2 mM L-glutamine.
The WNV-578/10 strain (GenBank accession number: KC496015) was originally isolated in Hungary
from a horse showing clinical signs of encephalitis, which had died in 2010.
2.2. RNA Extraction and cDNA Synthesis
Total RNA was extracted from virus pellet using the QIAamp Viral RNA Mini Kit (QIAGEN,
Hilden, Germany) following the manufacturer’s instructions. To obtain long cDNA copies of the
viral genome, reverse transcription was performed using the high fidelity SuperScript III First-Strand
Synthesis System (Invitrogen, Carlsbad, CA, USA) and gene-specific reverse primers (Table 1). In
the first step, 0.5 µL of each primer (10 µM) and 1 µL RNA in 7.5 µL RNase-free water were heated
to 65 ˝C for 5 minutes and then cooled down to 4 ˝C for 10 minutes. In the second step, 11 µL reaction
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mixture (2 µL reaction buffer, 4 µL MgCl2, 2 µL dithiothreitol (DTT), 1 µL RNase OUT inhibitor, 1 µL
SSIII enzyme and 1 µL dNTP mixture) were added and after 30 minutes at room temperature and the
final 20-µL reaction mixture was heated to 50 ˝C for 90 minutes, followed by 85 ˝C for 5 minutes, and
finally cooled down to 4 ˝C. Before amplification, cDNA was treated with RNase H (1 µL RNase H
was added to 20 µL of the above-mentioned solution and was heated to 37 ˝C for 20 minutes).
Table 1. List of primers used to generate overlapping fragments of the West Nile virus (WNV) genome
in order to construct the full-length clone pWNV-578/10.
Primer code Nucleotide sequence (5’Ñ3’) Nucleotide position (5’) *
1F† GAGCTCGTTTAGTGAACCGTAGTAGTTCGCCTGTGTGAGC 1
1FRC† GCTCACACAGGCGAACTACTACGGTTCACTAAACGAGCTC 20
4750F CACACACTATGGCACACCACTAAGG 4750
5426R GACATCAGCCTGTGTGTGAGAGTGG 5426
8190F AGACTGGCTGCACAGAGGACCTAAG 8190
9175R GGTCTTCATTGAGGAATCCGAGAGC 9175
3’XbaSacIIR‡ ATCCGCGGTCTAGAGATCCTGTGTTCTAGCACCACAG 11026
† Bases in italics are part of cytomegalovirus (CMV) promoter. * Primer positions corresponding to the sequence
of WNV-578/10 strain. ‡ Bases in italics are the extra restriction enzyme cleavage sites.
2.3. Sequence Analysis
The complete genome of WNV-578/10 was determined by sequencing of overlapping PCR
fragments amplified with Phusion Hot Start High-Fidelity DNA Polymerase (Finnzymes, Espoo,
Finland). Amplification products were directly sequenced with the ABI Prism BigDye Terminator V3.1
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and an automated ABI 377 DNA
Sequencer (Applied Biosystems). Sequence assembly and comparison were performed with SeqMan
and MegAlign programs (Lasergene, Madison, WI, USA), respectively. The full-length WNV clone was
sequenced with the ABI Prism BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems)
and an ABI Prism 310 genetic analyzer (Applied Biosystems), as described in Bakonyi et al., 2004 [39].
Full genome sequencing of WNV clones with the incorporated modifications was carried out by
using semiconductor sequencing technology. Briefly, overlapping PCR fragments were generated as
described above. Equimolar amounts of the amplicons from each clone were used for preparation of
Ion Torrent compatible libraries. Clonal amplification of library DNA (with 200 bp inserts) by emulsion
PCR on an Ion One Touch v2 (Life Technologies, Thermo Fisher Scientific, Waltham, MA, United
States) equipment was followed by enrichment on an Ion OneTouch ES pipetting robot, and then by
sequencing on a 316 Chip using Ion Torrent PGM (Life Technologies). Raw reads were curated and
then consensus genomic sequences were assembled using the CLC Genomics Workbench version 7
(www.clcbio.com).
2.4. Plasmids and Bacteria Strains
Plasmid pBeloBAC TGE [40] was kindly provided by L. Enjuanes (Centro Nacional de Biotecnologia,
Department of Molecular and Cell Biology, Madrid, Spain). The plasmid was propagated in Max
Efficiency DH10B competent Escherichia coli cells (Invitrogen) that were transformed by heat shock
according to the manufacturer’s instructions. Modifications, such as deletion of the XhoI site
downstream of the 3’ accessory sequences and insertion of a multiple cloning site containing SfiI,
SfoI, BstBI, ClaI, BamHI, XhoI, AsiSI, AvrII and SacII, were described earlier [41]. For large-scale DNA
preparation, the BAC vector and recombinant BACs were isolated with the QIAGEN Large Construct
Kit (QIAGEN) according to the manufacturer’s specifications.
2.5. Generation of the Full-Length Clone of WNV-578/10
To amplify long, overlapping PCR products, ranging between 1 and 5.5 kb covering the whole
genome in three fragments (Fragment I, II and III), PCRs were performed using genome-specific
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primers (Figure 1). Long-range PCR assays were implemented using the Phusion Hot Start
High-Fidelity DNA Polymerase (Finnzymes). The construction of Fragment I was performed in
two steps. First, the CMV promoter sequence from the PBeloBAC (with primers 5’SfiIF and 1FRC),
as well as the 5’ side of 5426 nucleotides of WNV-578/10 strain (with primers 1F and 5426R), were
amplified. Primers 1F and 1FRC were reverse complements. In the second step that joined together
the two amplicons, a fusion PCR utilizing the overlapping sequences of the above-mentioned primers
was performed with Phusion Hot Start High-Fidelity DNA Polymerase (Finnzymes). Fragment II
was amplified by using primers 4750F and 9175R. For amplification of Fragment III, a specific reverse
primer containing two extra restriction sites (XbaI and SacII) in addition to the 3’ conservative end of
WNV-578/10 strain (3’XbaSacIIR) and forward primer 8190F was used. Sequences of all the primers
used to generate the full-length clone are listed in Table 1. All fragments were separated and purified
from 0.8% agarose gel using the QIAquick Gel Extraction kit (Qiagen).
Restriction enzyme cleavage and cloning steps were performed according to standard
protocols [42]. Restriction endonucleases and DNA modifying enzymes were purchased from
Fermentas (Vilnius, Lithuania) and New England Biolabs (Beverly, MA, USA). The cDNA fragments
were ligated with T4 DNA Ligase (Invitrogen Life Technologies). After the digestion of pBeloBac
and fragment III with AvrII and SacII restriction endonucleases, fragment III was cloned into the
pBeloBac to obtain WNV-3. Fragment II was digested with BstBI and AvrII restriction endonucleases,
and was cloned into WNV-3 to get WNV-3-2. Fragment I was digested with SfiI and BstBI restriction
endonucleases, and was cloned into WNV-3-2 to obtain the final full-length clone pWNV-578/10. All
recombinant plasmids were stable in bacteria, and no toxicity was observed. All the sequences of
molecular constructs were confirmed by restriction endonuclease pattern analysis and PCRs.
Viruses 2016, 8, 49 
4 
2.5. Generation of the Full‐Length Clone of WNV‐578/10  
To amplify long, overlapping PCR products, ranging between 1 and 5.5 kb covering the whole 
genome  in  three  fragments  (Fragment  I,  II and  III), PCRs were performed using genome‐specific 
primers  (Figure  1).  Long‐range  PCR  assays  were  implemented  using  the  Phusion  Hot  Start  
High‐Fidelity DNA Polymerase (Finnzymes). The construction of Fragment I was performed in two 
steps. First, the CMV promoter sequence from the PBeloBAC (with primers 5’SfiIF and 1FRC), as well 
as the 5’ side of 5426 nucleotides of WNV‐578/10 strain (with primers 1F and 5426R), were amplified. 
Primers 1F and 1FRC were  reverse complements.  In  the second step  that  joined  together  the  two 
amplicons, a fusion PCR utilizing the overlapping sequences of the above‐mentioned primers was 
performed with Phusion Hot Start High‐Fidelity DNA Polymerase  (Finnzymes). Fragment  II was 
amplified by using primers 4750F and 9175R. For amplification of Fragment III, a specific reverse 
primer containing two extra restriction sites (XbaI and SacII) in addition to the 3’ conservative end of 
WNV‐578/10 strain (3’XbaSacIIR) and forward primer 8190F was used. Sequences of all the primers 
used to generate the full‐length clone are listed in Table 1. All fragments were separated and purified 
from 0.8% agarose gel using the QIAquick Gel Extraction kit (Qiagen).  
Restriction  enzyme  cleavage  and  cloning  steps  were  performed  according  to  standard  
protocols  [42].  Restriction  endonucleases  and  DNA  modifying  enzymes  were  purchased  from 
Fermentas (Vilnius, Lithuania) and New England Biolabs (Beverly, MA, USA). The cDNA fragments 
were ligated with T4 DNA Ligase (Invitrogen Life Technologies). After the digestion of pBeloBac and 
fragment III with AvrII and SacII restriction endonucleases, fragment III was cloned into the pBeloBac 
to obtain WNV‐3. Fragment II was digested with BstBI and AvrII restriction endonucleases, and was 
cloned  into  WNV‐3  to  get  WNV‐3‐2.  Fragment  I  was  digested  with  SfiI  and  BstBI  restriction 
endonucleases, and was cloned into WNV‐3‐2 to obtain the final full‐length clone pWNV‐578/10. All 
recombinant plasmids were stable  in bacteria, and no  toxicity was observed. All  the sequences of 
molecular constructs were confirmed by restriction endonuclease pattern analysis and PCRs. 
 
Figure 1. Cloning strategy  for  the WNV‐578/10 genome and positions of  the generated mutations. 
Black  numbers  represent  nucleotide  positions  in  WNV  genome/PBeloBac  plasmid  genome.  
Red numbers  indicate nucleotide positions of  restriction  enzyme  cleavage  sites  in WNV genome. 
Green numbers in boxes represent nucleotide positions of inserted mutations. Names of used primers 
are in blue.   
Figure 1. Cloning strategy for the WNV-578/10 genome and positions of the generated mutations.
Black numbers represent nucleotide positions in WNV genome/PBeloBac plasmid genome. Red
numbers indicate nucleotide positions of restriction enzyme cleavage sites in WNV genome. Green
numbers in boxes represent nucleotide positions of inserted mutations. Names of used primers are
in blue.
2.6. Generation of Mutant Full-Length WNV Clones
Point mutations were inserted in the genome of WNV using PCR-based mutagenesis utilizing
specific oligonucleotides (forward and reverse, complementary oligos) containing the altered
nucleotides (Table 2). Depending on the position of the mutation in the genome, new fragments I
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or II were synthesized using the mutated complementary oligos in fusion PCRs. In the next step,
the original fragment I or fragment II was removed from the pWNV-578/10 clone and was replaced
with the newly synthesized fragment I or fragment II, containing the respective mutations in the
pWNV-578/10 clone. The generated mutations were as follows: C3218T in NS1 protein gene (P250L),
G3613C in NS2A protein gene (A30P), C5357A in NS3 protein gene (P249H), and three mutations in
the NS4B protein gene: CC7030-31GG (P38G), G7223C (C102S) and A7664G (E249G) (Figure 1).
Table 2. List of primers used to insert point mutations into the genome of WNV-578/10.
Primer code Nucleotide sequence (5’Ñ3’) Nucleotide Position (5’)*
NS1F CATCACCTTGGCAGGACTCAGAAGCAATCATAACAGGAGACC 3201
NS1R GGTCTCCTGTTATGATTGCTTCTGAGTCCTGCCAAGGTGATG 3201
NS2AF TTCGCAAGAGGTGGACGCCCAAGATCAGCATTCCAGCTATCA 3596
NS2AR TGATAGCTGGAATGCTGATCTTGGGCGTCCACCTCTTGCGAA 3596
NS3F GGTACCAAACCTCAGCAGTGCACAGAGAGCACAGTGGAAATGA 5336
NS3R TCATTTCCACTGTGCTCTCTGTGCACTGCTGAGGTTTGGTACC 5336
38NS4BF TTCTTGCTTGATCTGCGGGGGGCTACAGCATGGTCTCTCTAT 7012
38NS4BR ATAGAGAGACCATGCTGTAGCCCCCCGCAGATCAAGCAAGAA 7012
102NS4BF TCAGCTCTCTTGCTGGCGGCCGGGTCCTGGGGCCAAGTGACCCTGACTGTGACT 7198
102NS4BR AGTCACAGTCAGGGTCACTTGGCCCCAGGACCCGGCCGCCAGCAAGAGAGCTGA 7198
249NS4BF GGACTCTCATCAAAAACATGGGGAAACCAGGCCTCAAGAG 7643
249NS4BR CTCTTGAGGCCTGGTTTCCCCATGTTTTTGATGAGAGTCC 7643
* Primer positions corresponding to the sequence of WNV-578/10. Triplets in italics are the loci of mutations,
modified nucleotides are in italics and bold.
2.7. Transfection and Recovery of the Recombinant Viruses from the cDNA Clones
Before transcription, the CMV-WNV clone was double digested with SfiI and XbaI restriction
endonucleases. To remove the single-stranded nucleotide overhang generated by the digestion, Mung
Bean Nuclease (New England Biolabs) was used. In order to get the purified expression cassette,
pieces from digestion were separated on a 0.8% agarose gel and the approximately 12 kb cassette was
purified with QIAquick Gel Extraction Kit (QIAGEN). Four micrograms of double-stranded cDNA
was transfected into BHK-21 cells using Turbofect in vitro Transfection Reagent (Thermo Scientific,
Waltham, MA USA). Briefly, 4 µg of plasmid DNA were transfected into an approximately 60%
confluent monolayer of BHK-21 cells on a 6-well culture plate after a 20 minute incubation period with
the Turbofect reagent. The plates were incubated for 4 h at 37 ˝C, then the supernatant was removed,
and fresh DMEM (Sigma-Aldrich, Saint Louis, MO, USA) supplemented with 10% FBS was added.
The cells were incubated at 37 ˝C for 48–96 h until a visible cytopathic effect (CPE) appeared. At this
time point, supernatant was harvested, clarified by centrifugation at 1000 ˆ g for 5 min, and stored
at –80 ˝C. To increase infectious virus titres for use in in vitro and in vivo experiments, virus stocks of
the recombinant wild type (WT) and mutant viruses were incubated on 80% monolayers of Vero E6
cells in cell culture flasks. At the point of maximum CPE (4–5 days after inoculation), supernatants
were harvested, clarified by centrifugation at 1000 ˆ g for 5 min, and stored at –80 ˝C. Infectious titres
of the virus stocks were determined by log10 titration on Vero E6 cells and calculating the TCID50 using
the Spearman–Kärber method [43,44] after determination of CPE 5 days p.i.
Subsequent full genome sequencing of each stock was performed by semiconductor sequencing
as detailed in Section 2.3.
2.8. Multiplication Curves in Cell Culture
Growth curves of the wild-type virus and the mutated clones were generated in Vero E6 cells
at 37 ˝C in two independent experiments. Vero E6 cells were seeded at 104 cells/well in flat-bottom
96-well plates, incubated overnight at 37 ˝C and 80% monolayers were infected in triplicate with 100 µL
of virus diluted in serum-free DMEM at multiplicity of infection (MOI) 0.1. Cells were incubated for
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1 h at 37 ˝C and subsequently washed three times with serum-free medium before adding 120 µL of
DMEM supplemented with 10% FCS. At 0, 12, 24, 36, 48, 72 and 96 h post-infection (p.i.), supernatants
were removed and 70 µL was frozen at –80 ˝C until used for infectious virus titre determination, while
the remaining 50 µL was added to 350 µL of lysis buffer (Roche Diagnostics, Almere, The Netherlands)
for RNA extraction. Cells were also collected for RNA extraction in 50 µL of lysis buffer at time points
0, 12, 36 and 48 h p.i. Harvested supernatant infectious virus titres were determined by log10 titration
on Vero E6 cells as described previously.
2.9. Quantitation of Viral RNA Titres
In order to quantify viral RNA copies in the supernatant and cells, RNA was extracted using the
MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics) and an automated nucleic acid
robotic workstation (Roche Diagnostics) according to the manufacturer’s instructions. RNA was eluted
in 50 µL of elution buffer and used immediately in quantitative real-time PCR (qRT-PCR). Within in vivo
experiments, viral RNA copies in half-brains were quantified after weighing and homogenization
using a metal bead in DMEM containing antibiotics (100 U penicillin, 100 µg/mL streptomycin) using
a tissue homogenizer. One hundred microliters of tissue homogenate was added to 400 µL of lysis
buffer (Roche Diagnostics) and RNA was extracted as indicated above. RNA copy numbers were
determined in a strand-specific qRT-PCR assay [45] using a standard curve of in vitro transcribed
RNA of positive and negative strand of known quantities, which were generated from a plasmid
(pCR®4-TOPO®; Invitrogen, Breda, The Netherlands) containing the sequence of the 3’UTR of WNV.
Plasmid was linearized and run-off transcripts were generated using the Ambion® MaxiScript T7/T3
kit (Invitrogen). The positive sense RNA was transcribed using the T3 polymerase and the negative
sense RNA using the T7 polymerase. The product was digested with DNase to remove residual DNA
and cleaned-up using the High Pure RNA Isolation kit (Roche Diagnostics). In vitro transcribed RNA
was diluted to a concentration at which DNA was no longer detected.
2.10. Mouse Virulence Studies
Six-week-old female C57BL/6 mice (Harlan Laboratories B.V., Venray, The Netherlands) were
inoculated intraperitoneally (i.p.) with average doses of 10 and 104 TCID50 per mouse of wild-type
infectious clone-derived CMV-WNV as well as the mutant viruses (n = 8 per clone, per dose; Table 3).
Mice were observed twice daily and were euthanized by cervical dislocation under isoflurane
anesthesia when humane endpoints were reached (immobility and paralysis), after which brains
were immediately collected for further processing. At 14 days p.i., the end-point for the survival
experiment was reached and all remaining mice were euthanized and brains and kidneys were
collected from those that had been infected with the highest viral dose. Mice were maintained in
specific pathogen-free conditions, had a 12-hour day-night cycle and were fed ad libitum. Animal
experiments were approved by the Animal Ethics Committee of Erasmus Medical Centre and carried
out under protocol number 122-13-19.
2.11. Statistical Analysis
Data analysis was performed using GraphPad Prism v5 software statistical analysis. The ANOVA
test was used for the comparison of more than two groups. Statistical significance between individual
groups was determined using the Mann-Whitney U test, and statistical significance was accepted
at p ď 0.05.
3. Results
3.1. Comparison of the Genome Sequences of WNV Lineage 1 (NY99) and Lineage 2 (578/10) Strains
The complete genome sequence of the 578/10 strain (GenBank accession number KC496015)
exhibits 2236 nucleotide (nt) differences (21%) compared to the WNV NY99 strain (accession number
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AF202541). The nucleotide substitutions are distributed fairly equally within the genome (5’UTR:
0 substitutions (0%), C protein gene: 59 substitutions (16%), preM-M protein gene: 102 substitutions
(21%), E protein gene: 309 substitutions (21%), NS1 protein gene: 227 substitutions (22%), NS2A
protein gene: 153 substitutions (23%), NS2B protein gene: 82 substitutions (22%), NS3 protein gene:
382 substitutions (21%), NS4A protein gene: 80 substitutions (22%), 2K gene: 13 substitutions (19%),
NS4B protein gene: 184 substitutions (25%), NS5 protein gene: 560 substitutions (21%), and 3’UTR:
90 substitutions (20%)). Within the putative polyprotein precursor, 203 amino acid (aa) alterations
(6%) are found (C protein: 12 substitutions (10%), preM-M protein: 7 substitutions (5%), E protein: 22
substitutions (5%), NS1 protein: 33 substitutions (10%), NS2A protein: 24 substitutions (11%), NS2B
protein: 7 substitutions (6%), NS3 protein: 25 substitutions (5%), NS4A protein: 7 substitutions (6%),
2K protein: 1 substitution (5%), NS4B protein: 19 substitutions (8%), and NS5 protein: 46 substitutions
(6%)). Due to this high level of sequence diversity, it is not possible to test the potential effect of
each substitution in all combinations. As a result, within this study we only tested the effect (in a
neuroinvasive WNV lineage 2 strain) of the nucleotide substitutions that have already been identified
as virulence markers in WNV lineage 1 strains.
3.2. Rescue of Recombinant Viruses
In order to investigate whether molecular markers of virulence identified in lineage 1 WNV strains
attenuate the Hungarian neuroinvasive lineage 2 WNV-578/10 strain in vitro or in vivo, infectious
cDNA clones encoding each substitution of interest were constructed and transfected into BHK-21 cells.
After transcription by CMV promoter, CPE had reached the maximum level at 72–96 h after transfection.
Supernatants were harvested and passed on Vero E6 cells, which resulted in the generation of at least
6 log10 TCID50/mL virus stocks. When the titre did not reach the desired level, one more passage in
Vero E6 cells was performed. All mutations of interest were verified by Sanger sequencing of each
stock before in vitro and in vivo characterization. The NS4B102 mutant recombinant WNV was unable
to multiply to a sufficient titre in BHK-21 cells nor after passage in Vero E6 cells, and this mutant clone
was therefore excluded from the functional analyses.
3.3. Full Genome Sequence Analysis of Recombinant Virus Stocks
To determine whether passaging the virus stocks led to the introduction of additional mutations,
the full genome of the wild type and modified clone virus stocks were sequenced. One nucleotide
alteration was found in addition to the mutated sites for three mutant clones, of which two out of three
nt changes were silent: G to A on locus 627 of the NS1 clone, and A to G on locus 6768 of the NS4B38
clone. One nt alteration in the genome of the NS4B249 clone resulted in a Valine to Isoleucine change
in the NS4B protein at locus 188 (G to A on locus 7480). The in vitro and in vivo characterization was
subsequently carried out using the generated clones.
3.4. Multiplication Kinetics of the Recombinant Wild Type (WT) and Mutant WNVs in Cell Culture
The multiplication kinetics of the mutant WNVs were compared to those of the WT infectious
clone-derived WNV-578/10 in Vero E6 cells infected in triplicate at an MOI of 0.1 at 37 ˝C, sampling
every 12 hours. Overall, the infectious virus titers of the clones were significantly different at all
time points between 12 h and 96 h p.i. (one way ANOVA; p < 0.02). More specifically, infectious
virus titres for WT were significantly higher at 24 h p.i. compared to all the mutated viruses; NS1
(p = 0.005), NS2A, NS3, NS4B38, and NS4B249 (p = 0.03). Moreover, NS1 infectivity titres were found
to be significantly lower compared to NS2A (p = 0.03) and NS4B38 (p = 0.03) (Figure 2). At 36 h p.i.,
WT infectivity titres were only significantly higher compared to NS1 (p = 0.002), NS2A and NS3 (both
p = 0.02). At this time point, the difference in infectious virus titres between WT and NS1 was the
largest, at approx. 2500-fold. In addition, NS1 titres remained significantly lower compared to all the
other viral clones (all, p = 0.03). At 48 h p.i., WT infectious titres were still significantly higher compared
to NS1 (p = 0.005), NS2A and NS3 (p = 0.03), while NS1 titres were only significantly lower compared
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to NS2A (p = 0.04) and NS4B249 (p = 0.03). At 72 and 96 h p.i., WT infectious titres remained only
significantly higher compared to NS1 (p = 0.005; 0.02, respectively), while NS1 titres were significantly
lower compared to all the other WNV strains at 72 h p.i. (p < 0.04), and compared to NS4B38 and
NS4B249 at 96 h p.i. (p < 0.04).
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triplicate  infection  of  Vero  E6  cells  at  an  MOI  of  0.1.  The  titres  are  given  as  the  mean  
(log10 TCID50/mL); error bars represent standard deviation. 
3.5. Quantification of Positive and Negative Strand RNA for WT and NS1 Mutant in Vitro 
In order to assess whether the in vitro replication differences between the WT and NS1 mutant 
can be attributed to differences in positive and negative strand RNA synthesis, we determined the 
amount  of positive  and  negative  strand RNA  copies  in  the  supernatant  and  cells  of  the  in  vitro 
multiplication  kinetics  experiment  using  a  strand‐specific  qRT‐PCR  assay  [45].  The  amount  of 
positive strand present in the supernatant was more than 1 log10 higher for NS1 compared to WT at 
12 h p.i., albeit not statistically significant (p > 0.05) (Figure 3a). At 24 h p.i., positive strand titres were 
approx. 0.9 log10 RNA copies higher for the WT compared to NS1 (p = 0.002). This difference increased 
to approx. 1.4 log10 RNA copies by 36 h p.i. (p = 0.002) and 1.3 log10 at 48 h p.i. (p = 0.002). At t = 72, 
titre differences had decreased to 0.8 log10 (p = 0.002) and at 96 h p.i. positive strand titres were only 
Figure 2. Growth kinetics of infectious virus of the wild type (WT) virus and mutant viruses after
triplicate infection of Vero E6 cells at an MOI of 0.1. The titres are given as the mean (log10 TCID50/mL);
error bars represent standard deviation.
3.5. Quantification of Positive and Negative Strand RNA for WT and NS1 Mutant in Vitro
In order to assess whether the in vitro replication differences between the WT and NS1 mutant can
be attributed to differences in positive and negative strand RNA synthesis, we determined the amount
of positive and negative strand RNA copies in the supernatant and cells of the in vitro multiplication
kinetics experiment using a strand-specific qRT-PCR assay [45]. The amount of positive strand present
in the supernatant was more than 1 log10 higher for NS1 compared to WT at 12 h p.i., albeit not
statistically significant (p > 0.05) (Figure 3a). At 24 h p.i., positive strand titres were approx. 0.9 log10
RNA copies higher for the WT compared to NS1 (p = 0.002). This difference increased to approx. 1.4
log10 RNA copies by 36 h p.i. (p = 0.002) and 1.3 log10 at 48 h p.i. (p = 0.002). At t = 72, titre differences
had decreased to 0.8 log10 (p = 0.002) and at 96 h p.i. positive strand titres were only 0.6 log10 RNA
copies higher for WT compared to NS1, although still significantly different (p = 0.04) (Figure 3a).
Positive strand intracellular RNA titres were initially also higher for NS1 compared to WT for the
first 12 h p.i. (Figure 3b). However, after 24 h p.i., WT positive strand RNA titres had become approx.
0.9 log10 RNA copies higher compared to NS1 (p = 0.002), with the most pronounced difference of
approx. 1 log10 RNA copies after 36 h p.i. (p = 0.002). At 48 h p.i., positive strand RNA titres were
still significantly higher for the WT compared to NS1 (p = 0.004) but the difference had decreased to
approx. 0.6 log10 RNA copies (Figure 3b).
For intracellular negative strand RNA copies, titres for NS1 were already significantly lower
compared to the WT at 12 h p.i. (p = 0.02) (Figure 3c). NS1 negative strand RNA copies remained
significantly lower compared to the WT with a difference of approx. 1.2 log10 RNA copies at both 24
and 36 h p.i. (p = 0.002). After 48 h p.i., titre differences decreased to approx. 0.4 log10 RNA copies, at
which point the difference was no longer statistically significant (p = 0.06) (Figure 3c).
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Figure 3. Quantification of (a) extracellular positive strand RNA (b) intracellular positive strand RNA, 
and (c) negative strand RNA for WT and NS1 mutant after triplicate infection of Vero E6 cells at an 
MOI of 0.1. Copy numbers are given as the mean of two independent experiments (log10 TCID50/mL); 
error bars represent standard deviation. 
3.6. Mouse Neuroinvasiveness of the Different Mutant WNV Strains 
The  mouse  neuroinvasive  phenotype  of  each  mutant  WNV  was  examined  following  i.p. 
inoculation of six‐week‐old female C57BL/6 mice. Compared to the WT (100% and 75% mortality at 
high and low doses, respectively), only the NS1 mutant proved to be significantly attenuating since 
all mice infected with either the high or low dose of this virus survived the infection (0% mortality 
for both) (Table 3; Figure 4a and 4b). In contrast, mice  infected with the highest dose of the other 
mutant strains experienced substantial mortality, with rates of 100% (8/8) for NS4B38, 88% (7/8) for 
NS2A, 75%  (6/8)  for NS3, and 63%  (5/8)  for NS4B249,  respectively  (Figure 4a). Statistical analysis 
confirmed  the  attenuation of  the NS1 mutant,  as  significant differences were  found between  the 
survival curves of mice  infected with  the highest dose of NS1 as compared  to  the WT  (p<0.0001), 
NS2A (p = 0.0004), NS3 (p = 0.003), NS4B38 (p = 0.0002) and NS4B249 (p = 0.008). On the other hand, 
the  high dose  survival  curves  6of  the  other mutant WNVs  showed  no  significant differences  in 
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Figure 3. Quantification of (a) extracellular positive strand RNA (b) intracellular positive strand RNA,
and (c) negative strand RNA for WT and NS1 mutant after triplicate infection of Vero E6 cells at an
MOI of 0.1. Copy numbers are given as the mean of two independent experiments (log10 TCID50/mL);
error bars represent standard deviation.
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3.6. Mouse Neuroinvasiveness of the Different Mutant WNV Strains
The mouse neuroinvasive phenotype of each mutant WNV was examined following i.p.
inoculation of six-week-old female C57BL/6 mice. Compared to the WT (100% and 75% mortality at
high and low doses, respectively), only the NS1 mutant proved to be significantly attenuating since
all mice infected with either the high or low dose of this virus survived the infection (0% mortality
for both) (Table 3; Figure 4a,b). In contrast, mice infected with the highest dose of the other mutant
strains experienced substantial mortality, with rates of 100% (8/8) for NS4B38, 88% (7/8) for NS2A,
75% (6/8) for NS3, and 63% (5/8) for NS4B249, respectively (Figure 4a). Statistical analysis confirmed
the attenuation of the NS1 mutant, as significant differences were found between the survival curves of
mice infected with the highest dose of NS1 as compared to the WT (p<0.0001), NS2A (p = 0.0004), NS3
(p = 0.003), NS4B38 (p = 0.0002) and NS4B249 (p = 0.008). On the other hand, the high dose survival
curves 6of the other mutant WNVs showed no significant differences in comparison to the WT, or
compared to each other.Viruses 2016, 8, 49 
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Figure  4.  Survival  of  six‐week‐old  female C57/Bl6 mice  after  i.p.  inoculation, with  (a)  high dose  
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Figure 4. Survival of six-week-old female C57/Bl6 mice after i.p. inoculation, with (a) high dose
(104 TCID50) and (b) low dose (10 TCID50) of recombinant WNVs.
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Mortality rates of mice infected with the lowest viral dose of the other mutant strains
were 75% (6/8) for NS2A, 63% (5/8) for NS4B38, 50% (4/8) for NS4B249 and 38% (3/8) for NS3
(Table 3; Figure 4b). The lower dose survival curves of NS1-infected mice were also significantly
different when compared to the WT (p = 0.002), NS2A (p = 0.002), NS4B38 (p = 0.009) and NS4B249
(p = 0.03). In contrast, the survival curves of the other mutants were not significantly different compared
to the WT, or each other.
Table 3. Mortality data of six-week-old female C57BL/6 mice inoculated i.p. with high and low doses
of the WT and mutant lineage 2 WNVs.
Virus Dose (TCID50) Total mortality Mortality (%) Median day
WT 10ˆ5 8/8 100 10.5
WT 10ˆ1 6/8 75 11
NS1 10ˆ4 0/8 0 NA
NS1 10ˆ1 0/8 0 NA
NS2a 10ˆ5.5 7/8 88 9
NS2a 10ˆ1 6/8 75 11.5
NS3 10ˆ3 6/8 75 10.5
NS3 10ˆ0 3/8 38 11
NS4B38 10ˆ4 8/8 100 11
NS4B38 10ˆ0 5/8 63 11
NS4B249 10ˆ4 5/8 63 9
NS4B249 10ˆ1 4/8 50 11.5
3.7. Sequencing of Recombinant WNV in Organs of Euthanized and Survivor Mice
All mice euthanized due to illness were found to be positive for viral RNA in the brain (data
not shown). To determine whether the mutant strains detected in the brains of mice euthanized
due to illness after infection with the highest viral dose had retained the original mutation, viral
RNA obtained from two mouse brains per group was sequenced. It was found that the consensus
sequences of the virus strains present in the selected mouse brains still contained the original mutation
and therefore had not reverted to the wild-type. Additionally, we also determined the presence of
persisting virus in the brain and kidney of all mice that had survived infection (euthanized on day 14
p.i.) with the highest dose of the different mutant virus strains (NS1, n = 8; NS2A, n = 1; NS3, n = 2;
and NS4B249, n = 3) using qRT-PCR. All brains positive for viral RNA were sequenced in order to
check for the presence of the original mutation. Out of the eight mice that survived infection with NS1,
only one mouse was found to be positive for virus in the brain, which had reverted to the wild-type.
For NS2A, the one survivor mouse was found to be positive for viral RNA in the kidney, which still
contained the original mutation. Out of the two mice that had survived infection with NS3, and out of
the two mice surviving infection with NS4B249, only one mouse in each group was positive for viral
RNA in the brain, which was also found to have retained the original mutation.
4. Discussion
The aim of this study was to generate a full-length infectious clone of the WNV lineage 2
strain 578/10 that has recently been detected in central Europe, in order to improve our understanding
on the genetic background of WNV pathogenicity. Infectious cDNA clones are useful tools
to investigate genetic determinants of flavivirus virulence, for studying its replication, creating
subgenomic replicons, and using gene expression or gene of interest insertions [46–48]. Full-length
infectious WNV clones are often constructed by fusion (stitching) polymerase chain reactions or
plasmid-based methods [49–52]. Since assembly of full-length flavivirus clones in plasmid vectors
have proven to be toxic, or unstable and deleterious for bacterial hosts, on several occasions [53–56], we
cloned the full-length genome of WNV-578/10 using a bacterial artificial chromosome (BAC) [57]. This
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system contains the cytomegalovirus (CMV) immediate-early promoter that allows transcription of
WNV RNA in the nucleus by cellular RNA polymerase II, eliminating the step of in vitro transcription.
WNVs belonging to lineage 2 were previously considered as agents of low pathogenicity [10];
however, numerous neuroinvasive and highly pathogenic members have recently been identified in
horses and humans suffering from severe encephalitis in South Africa [58]. WNV strains belonging
to lineage 2 have also been reported in Hungary and surrounding countries since its first proven
appearance outside of Africa in 2004. During the last decade, several fatal cases among horses and
humans were confirmed as West Nile encephalitis caused by these lineage 2 viruses in the Central
European region [15,20]. The changing epidemiology and pathogenicity of WNV outbreaks in Europe
highlight our need to further understand how Central European WNV lineage 2 strains differ in their
capacity to cause severe disease compared to lineage 1 strains. Furthermore, this study may also
provide invaluable information for the development of safe and efficacious vaccines.
Several studies have identified and proven the role of genetic markers in the NS proteins of
lineage 1 WNV strains in pathogenicity and virulence studies [24,26,30,31,33–36]. On the other hand,
virulence markers of lineage 2 WNV strains have so far only been identified in silico by analyzing and
comparing full genome sequences [37,38]. Thus far, it is known that flaviviral NS proteins are essential
for virus replication; NS1, NS3, NS4A and NS4B can reorganize cellular membranes to generate
virus-induced membrane structures (IMS) for site of replication [59]. Furthermore, NS2A [24], NS2B,
NS3, NS4A [60], NS4B [61,62] and NS5 [63] play a role in virion assembly and evasion of host innate
immune responses by blocking the interferon (IFN) signal transduction pathway [64–66].
The flavivirus nonstructural protein NS1 is a glycoprotein with three conserved N-linked
glycosylation sites, and has an essential role in viral RNA replication. Normally, NS1 exists as a
heat labile homodimer that associates with cellular organelle membranes and is transported to the cell
surface [67,68]. Cell surface associated NS1 appears to have an immunomodulatory function via the
decrease of the complement activation by different routes [69,70]. NS1 is also secreted by mammalian
cells as a soluble hexamer [71,72].
Inclusion of the mutation P250L in a conserved region of the Kunjin virus NS1 gene has been
shown to affect the structure of the polypeptide, resulting in the inhibition of dimer formation but still
allowing its secretion in the monomeric form. The conformational change resulting from the P250L
mutation may have led to the decreased levels of infectious virus titres observed in Vero cells in the
early phase of replication (100-fold lower between 12–24 h p.i., compared to the WT); however, this
difference gradually decreased and eventually disappeared by 48 h p.i. [73]. Similar to this study, our
NS1 mutant also showed a 100-fold decrease in infectious virus; however, this was starting from 24 h
p.i. lasting until 48 h p.i., after which the difference was approx. 10-fold until 96 h p.i. We investigated
these observations further by quantifying the amount of positive and negative stranded RNA during
the first 48 hours of replication in order to determine whether the mutation affected the replication
process. We found that the NS1 mutant exhibited significantly slower replication as measured by an
approx. 10-fold reduced amount of both negative and positive stranded RNA in the cells, as well as
positive stranded RNA in the supernatant.
A role for the importance of NS1 in the process of RNA synthesis has already been described in
previous studies. Youn et al. found that WNV RNA lacking intact NS1 genes was efficiently translated
but did not form canonical replication complexes early after infection, resulting in a failure to replicate
viral RNA and consequently significantly lower amounts of positive and negative stranded RNA in
the cells [74]. As we also found a reduced amount of negative and positive stranded RNA for the
NS1 deletion mutant as compared to the WT during the first 48 hours of infection, it suggests that the
P250L mutation potentially affects the activity or the stability of the NS1 protein for the formation of
replication complexes during infection.
In the study by Hall et al., 10-fold more virus of the WNV-KUN P250L mutant was required to
produce disease in mice. Our results, however, show that this mutation completely abolished the
neuroinvasiveness of the lineage 2 WNV-578/10 strain, since no mice died after challenge with either
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the high or low dose of the virus. This means that in contrast to the Kunjin virus, neuroinvasiveness
had decreased at least 10,000 fold for our mutant virus. It is possible that the different mouse model
used in the aforementioned study (BALB/c mice) or the different age (18–20 days of age) of the mice
explains the discrepancy between our results. However, it can also not be excluded that the silent
mutation on locus 627 of the NS1 clone that we identified during full genome sequencing influenced
the attenuated phenotype of this mutant. Furthermore, the presence of certain loci in the genome of
the lineage 2 virus may have also augmented the attenuating effect of the P250L mutation observed
in our study as compared to those involving lineage 1. Studies involving the introduction of this
mutation into other, virulent lineage 1 or 2 WNV strains may provide more insight into the importance
of this mutation.
Nonetheless, the significantly reduced replication of the NS1 mutant that we observed in cell
culture may explain the reduced neuroinvasiveness observed in our study, as it may allow for early
control of the immune system followed by elimination of the virus before it has reached the central
nervous system. Even though only one mouse out of eight infected with the NS1 mutant was found to
have virus in the brain at day 14 p.i. (albeit lacking the original mutation), we cannot rule out with
certainty that the virus had still entered the brain in the majority of mice but had simply been cleared
by day 14 p.i. due to its reduced neurovirulence. Future experiments involving intracranial injections
of the NS1 mutant could confirm the reduced neurovirulent or neuroinvasive capacity of the virus.
NS2A is a small, hydrophobic, membrane-associated protein of WNV, believed to anchor the RNA
replication complex by intercalating into the endoplasmic reticulum (ER) membrane [75]. The NS2A
protein plays an important role in virus assembly and in the inhibition of the cellular antiviral response
via the inhibition of IFN-beta promoter-driven transcription [32,76]. In one study, a NY99 mutant virus
was less virulent in four-week-old Swiss-Webster outbred mice when the NS2A locus was derived
from the Kunjin virus and harbored an introduced A30P mutation [26]. In contrast, Rossi et al. found
only a slight decrease in virulence of the NS2A A30P mutant NY99 strain compared to the WT virus in
five-week-old Swiss-Webster mice [25]. Our results are in line with the latter study, as we observed no
significant differences in the replication kinetics of the mutant compared to the wild type virus, and no
significant attenuation was detected in mice after challenge.
The full length NS3 protein is a multifunctional enzyme (the N terminal residues encode
trypsin-like serine protease, the C terminal residues encode RNA triphosphatase, NTPase and helicase)
that possesses various activities in both viral polyprotein processing and RNA replication [77,78].
NS3 is suggested to be involved in virus assembly as well, but in cooperation with NS2A [79]. In
corvids, the lineage 1 NY99 virus containing a proline to threonine substitution at the NS3-249 locus
was particularly attenuating (100% to 12.5%), while the introduction of a proline at this site in a low
virulent strain led to an increase in virulence (31% to 94%), likely related to an increased capacity of
the virus to replicate in corvids [33]. This site therefore appears to be a key virulence determinant of
the lineage 1 NY99 strain in corvids; however, the influence of this mutation in a mouse model has
been minimal [80].
Genetic comparison of the goshawk-Hungary-2004 strain with the closely related lineage 2 Nea
Santa-Greece-2010 identified an H249P mutation, which was speculated to play a role in the increased
virulent phenotype of this Greek strain [18]. Interestingly, like the Greece-10 strain, our Hungarian
lineage 2 WNV-578/10 strain also contains a proline at this position (data not shown). As a result, we
investigated whether the NS3-249P mutation may contribute to increased virulence by introducing an
NS3-P249H substitution and testing its attenuation in a mouse model. Here, this substitution proved
to be slightly attenuating, but this was not statistically significant. Interestingly, infectious virus titres
obtained in cell culture were found to be significantly lower for NS3 compared to the wild-type at
three time-points. It should be noted, however, that this was also the case for several of the other
mutants, such as NS2A, which had not shown any attenuation in our mouse model. It therefore
appears that infectious virus titres in vitro do not correlate with attenuation in vivo. Indeed, in a study
by Langevin et al., despite the NS3-P249T mutation contributing to a 6 log10 PFU/mL lower titre in
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corvids, there were no significant differences observed in mean peak infectious viral titres on Vero
cells at 37 ˝C for this mutant when compared to the NS3-249P virus [80]. As we were interested in
examining the effect of the different mutations in a murine model, no thermosensitivity experiments
at temperatures higher than 37 ˝C were undertaken for any of the clones; however, further studies
testing the different mutants in cell culture at a higher temperature (41–44 ˝C) or in a corvid model
might prove to be insightful as well, as in particular mutations at the NS3-249 locus seem to play an
important role in the virulence of WNV in bird species.
Flaviviral NS4B is a predominantly helical, hydrophobic, membrane-associated NS protein, which
plays a crucial role in blocking host cell antiviral responses. It acts as an interferon antagonist, since
expression of NS4B, contributed by the activity of NS4A and NS2A, strongly inhibits the IFN-induced
signal transduction cascade by blocking STAT-1 phosphorylation [61]. Amino acid mutations in the
coding region of NS4B can alter the inhibitory effect on interferon signaling [62].
The P38 residue of NS4B is predicted to localize to the junction of an ER-luminal region and
a transmembrane domain. A study by Welte et al. found that the P38G mutation in the NS4B
protein induced a lower level of viremia and no lethality in six- to ten-week-old C57BL/6 mice, while
inducing higher type 1 IFNs and interleukin (IL)-1 as well as stronger effector and memory T cell
responses [35]. A later study by Wicker et al. found the NS4B-P38G substitution to be associated with a
temperature-sensitive phenotype of the lineage 1 NY99 strain, which involved a significant delay in
multiplication in Vero cells at 41 ˝C, but not at 37 ˝C, as well as attenuation for neuroinvasiveness with
an i.p. LD50 value of greater than 10,000 PFU in three- to four-week-old NIH Swiss mice. Importantly,
however, two unexpected additional mutations were found at NS4B-T116I and NS3-N480H and
actually none of the mutations alone were attenuating in mice [36]. In our study, the P38G mutation
did not affect replication in Vero E6 cells and the virus was equally virulent in mice as the WT, where
we used the same mouse strain and age as Welte et al. Furthermore, full genome sequencing revealed
that the NS4B-T116I and NS3-N480H mutations were not present in our NS4B38 clone. Even though it
is tempting to speculate that the P38G mutation may therefore not be so important for a lineage 2 WNV
strain, we cannot exclude that the presence of other co-mutations, such as the silent mutation at the
6768 locus that we identified during full genome sequencing, or other mutations specifically present in
the lineage 1 genetic backbone, are important for the attenuating effect of the NS4B-P38G mutation.
The C102S substitution of the NS4B protein in the NY99 strain has demonstrated thermosensitivity
at 41 ˝C in vitro and was found to attenuate mouse neuroinvasiveness and neurovirulence [29]. The
same substitution in the 578/10 construct dramatically reduced the replicative ability of the virus
in vitro as such that no virus could be rescued, and therefore its further in vitro and in vivo effect could
not be assessed. The hypothesized mechanism of C102S attenuation of the NY99 strain was a reduced
ability in inhibiting the IFN signaling pathway [29]. However, the C102S mutant 578/10 clone was
not able to replicate in BHK-21 and Vero E6 cells, even though the IFN-α and -β pathways are not
functioning in these cell lines. Therefore, probably other factors contributed to the lethal effect of this
substitution in the lineage 2 WNV strain.
The NS4B-E249G mutation has been observed in several natural WNV isolates [81,82].
Furthermore, it was shown that a mutant lineage 1 WNV containing the E249G residue replicated
at a lower level in C3H/He and BHK-21 cell cultures, but only slightly lower in Vero cell culture.
In addition, the E249G mutant lineage 1 WNV was significantly attenuating in six-week-old C3H/HeN
mice after footpad inoculation (100% mortality vs. 50%) [30]. On the other hand, a study by Rossi et al.
reported that a WNV lineage 1 virus harboring the NS4B-E249G mutation demonstrated a WT
phenotype with foci identical in size to the WT, as well as a similar LD50 value in i.p. inoculated
five-week-old Swiss-Webster mice [25]. Our results are closer to those obtained by Rossi et al. [25], as
the E249G mutant lineage 2 WNV propagated to similar titres in Vero E6 cells as the WT and showed
reduced mortality in mice (63%) that was not significantly different. It cannot be excluded, however,
that the non-conservative mutation found at NS4B188 played an important role in decreasing the
attenuated phenotype exerted by the NS4B-E249G mutation.
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In summary, our results have shown that in mammalian in vitro and in vivo models the NS1-P250L
mutation contributed to significant attenuation of lineage 2 WNV, while the NS3-H249P and
NS4B-E249G mutations conferred a partial, but not statistically significant reduction of virulence
in mice. In contrast, the NS2A-A30P and NS4B-P38G were not attenuating at all in vivo. Even though
it might be possible to conclude that the mutation at the NS1 locus could be an important marker
of virulence in lineage 2 WNV strains, the fact that lineage 1 mutation studies as cited herein often
showed varying results means that such results should still be addressed with caution. For example,
mouse genotype and age may have an important influence on the outcome of mutational studies
in vivo. The influence of other mutations in the particular genetic backbone used in certain studies may
also play an important role. To be specific, the genetic backbone of the lineage 2 virus that we used
may play a role in decreasing the attenuation of some of the markers that we have investigated, as well
as in increasing the attenuation of the NS1 mutation. As a result, future studies investigating details
of the NS1-P250L substitution should be performed in another vertebrate model, and also studies
involving the introduction of this particular NS1 mutation into the genome of other lineage 2 viruses,
or introducing the entire WNV-578 NS1 locus harboring this particular mutation into a lineage 1 strain,
may prove to be insightful.
The infectious clone described in this study provides a useful tool for testing the effect of
hypothetical virulence marker loci in in vitro and in vivo model systems. Within the last decade,
virulent lineage 2 WNV strains have emerged in Europe. For example, a descendant of the strain
that had emerged in 2004 in Hungary caused an epidemic with an unforeseen large amount of
neuroinvasive cases in Greece, in 2010. Another lineage 2 strain (Reb_VLG_07_H, GenBank accession
FJ425721) emerged in the Volgograd region of Russia and caused human neurological cases [21,22]. In
2010, this strain also emerged in south-east Romania [23] and survived for at least three years [83]. As
a result, genetic comparisons of different emergent isolates may help to identify and predict potential
virulence markers. In this regard, our study has provided more insight into genetic markers that may
contribute to the virulence of lineage 2 WNV strains.
Acknowledgments: The research leading to these results has received funding from the European Community's
Seventh Framework Program (FP7/2007 - 2013) under the project "VECTORIE”, EC grant agreement number
261466. The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the
views of the European Commission.
Author Contributions: T.B., A.B., B.M. and A.O. conceived and designed the experiments; K.S-G., S.L., L.D., K.B.,
P.K. and B.M. performed the experiments; K.S-G. and S.L. analyzed the data; K.B. performed whole-genome
sequencing related bioinformatics; K.S-G., S.L., A.B., B.M. and T.B. wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Mackenzie, J.S.; Williams, D.T. The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and
Australasia: the potential for emergent viruses. Zoonoses Public Health 2009, 56, 338–356. [CrossRef]
2. Pachler, K.; Lebl, K.; Berer, D.; Rudolf, I.; Hubalek, Z.; Nowotny, N. Putative new West Nile virus lineage
in Uranotaenia unguiculata mosquitoes, Austria, 2013. Emerg. Infect. Dis. 2014, 20, 2119–2122. [CrossRef]
[PubMed]
3. Kemenesi, G.; Dallos, B.; Oldal, M.; Kutas, A.; Foldes, F.; Nemeth, V.; Reiter, P.; Bakonyi, T.; Banyai, K.; Jakab, F.
Putative novel lineage of West Nile virus in Uranotaenia unguiculata mosquito, Hungary. Virusdisease 2014,
25, 500–503. [CrossRef] [PubMed]
4. Smithburn, K.C.; Hughes, T.P.; Burke, A.W.; Paul, J.H. A neurotropic virus isolated from the blood of a native
of Uganda. Am. J. Trop. Med. Hyg. 1940, 20, 471–492.
5. Jupp, P.G. The ecology of West Nile virus in South Africa and the occurrence of outbreaks in humans.
Ann. N. Y. Acad. Sci. 2001, 951, 143–152. [CrossRef]
Viruses 2016, 8, 49 16 of 20
6. Sotelo, E.; Fernandez-Pinero, J.; Llorente, F.; Vazquez, A.; Moreno, A.; Aguero, M.; Cordioli, P.; Tenorio, A.;
Jimenez-Clavero, M.A. Phylogenetic relationships of Western Mediterranean West Nile virus strains
(1996-2010) using full-length genome sequences: single or multiple introductions? J. Gen. Virol. 2011,
92, (Pt 11). 2512–2522. [CrossRef] [PubMed]
7. Hayes, C.G. West Nile virus: Uganda, 1937, to New York City, 1999. Ann. N. Y. Acad. Sci. 2001, 951, 25–37.
[CrossRef]
8. Zeller, H.G.; Schuffenecker, I. West Nile virus: an overview of its spread in Europe and the Mediterranean
basin in contrast to its spread in the Americas. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23, 147–156. [CrossRef]
[PubMed]
9. Calistri, P.; Giovannini, A.; Hubalek, Z.; Ionescu, A.; Monaco, F.; Savini, G.; Lelli, R. Epidemiology of west
nile in europe and in the mediterranean basin. Open Virol. J. 2010, 4, 29–37. [CrossRef]
10. Petersen, L.R.; Roehrig, J.T. West Nile virus: a reemerging global pathogen. Emerg. Infect. Dis. 2001, 7,
611–614. [CrossRef]
11. Bakonyi, T.; Ivanics, E.; Erdelyi, K.; Ursu, K.; Ferenczi, E.; Weissenbock, H.; Nowotny, N. Lineage 1 and
2 strains of encephalitic West Nile virus, central Europe. Emerg. Infect. Dis. 2006, 12, 618–623. [CrossRef]
[PubMed]
12. Erdelyi, K.; Ursu, K.; Ferenczi, E.; Szeredi, L.; Ratz, F.; Skare, J.; Bakonyi, T. Clinical and pathologic features
of lineage 2 West Nile virus infections in birds of prey in Hungary. Vector Borne Zoonotic Dis. 2007, 7, 181–188.
[CrossRef] [PubMed]
13. Krisztalovics, K.; Ferenczi, E.; Molnar, Z.; Csohan, A.; Ban, E.; Zoldi, V.; Kaszas, K. West Nile virus infections
in Hungary, August-September 2008. Euro. Surveill. 2008, 13, pii: 19030. [PubMed]
14. Wodak, E.; Richter, S.; Bago, Z.; Revilla-Fernandez, S.; Weissenbock, H.; Nowotny, N.; Winter, P. Detection
and molecular analysis of West Nile virus infections in birds of prey in the eastern part of Austria in 2008
and 2009. Vet. Microbiol. 2011, 149, 358–366. [CrossRef] [PubMed]
15. Bakonyi, T.; Ferenczi, E.; Erdelyi, K.; Kutasi, O.; Csorgo, T.; Seidel, B.; Weissenbock, H.; Brugger, K.; Ban, E.;
Nowotny, N. Explosive spread of a neuroinvasive lineage 2 West Nile virus in Central Europe, 2008/2009.
Vet. Microbiol. 2013, 165, 61–70. [CrossRef]
16. Ciccozzi, M.; Peletto, S.; Cella, E.; Giovanetti, M.; Lai, A.; Gabanelli, E.; Acutis, P.L.; Modesto, P.; Rezza, G.;
Platonov, A.E.; Lo Presti, A.; Zehender, G. Epidemiological history and phylogeography of West Nile virus
lineage 2. Infect. Genet. Evol. 2013, 17, 46–50. [CrossRef] [PubMed]
17. Chaskopoulou, A.; Dovas, C.I.; Chaintoutis, S.C.; Kashefi, J.; Koehler, P.; Papanastassopoulou, M. Detection
and early warning of West Nile Virus circulation in Central Macedonia, Greece, using sentinel chickens and
mosquitoes. Vector Borne Zoonotic Dis. 2013, 13, 723–732. [CrossRef] [PubMed]
18. Papa, A.; Bakonyi, T.; Xanthopoulou, K.; Vazquez, A.; Tenorio, A.; Nowotny, N. Genetic characterization of
West Nile virus lineage 2, Greece, 2010. Emerg. Infect. Dis. 2011, 17, 920–922. [CrossRef] [PubMed]
19. Bagnarelli, P.; Marinelli, K.; Trotta, D.; Monachetti, A.; Tavio, M.; Del Gobbo, R.; Capobianchi, M.; Menzo, S.;
Nicoletti, L.; Magurano, F.; et al. Human case of autochthonous West Nile virus lineage 2 infection in Italy,
September 2011. Euro. Surveill. 2011, 16.
20. Savini, G.; Capelli, G.; Monaco, F.; Polci, A.; Russo, F.; Di Gennaro, A.; Marini, V.; Teodori, L.; Montarsi, F.;
Pinoni, C.; et al. Evidence of West Nile virus lineage 2 circulation in Northern Italy. Vet. Microbiol. 2012, 158,
267–273. [CrossRef]
21. Platonov, A.E.; Fedorova, M.V.; Karan, L.S.; Shopenskaya, T.A.; Platonova, O.V.; Zhuravlev, V.I. Epidemiology
of West Nile infection in Volgograd, Russia, in relation to climate change and mosquito (Diptera: Culicidae)
bionomics. Parasitol. Res. 2008, 103 Suppl. 1, S45–S53. [CrossRef] [PubMed]
22. Platonov, A.E.; Karan, L.S.; Shopenskaia, T.A.; Fedorova, M.V.; Koliasnikova, N.M.; Rusakova, N.M.;
Shishkina, L.V.; Arshba, T.E.; Zhuravlev, V.I.; Govorukhina, M.V.; et al. [Genotyping of West Nile fever virus
strains circulating in southern Russia as an epidemiological investigation method: principles and results].
Zh. Mikrobiol. Epidemiol. Immunobiol. 2011, 29–37.
23. Sirbu, A.; Ceianu, C.S.; Panculescu-Gatej, R.I.; Vazquez, A.; Tenorio, A.; Rebreanu, R.; Niedrig, M.;
Nicolescu, G.; Pistol, A. Outbreak of West Nile virus infection in humans, Romania, July to October 2010.
Euro. Surveill. 2011, 16.
Viruses 2016, 8, 49 17 of 20
24. Liu, W.J.; Wang, X.J.; Clark, D.C.; Lobigs, M.; Hall, R.A.; Khromykh, A.A. A single amino acid substitution in
the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction
and attenuates virus virulence in mice. J. Virol. 2006, 80, 2396–2404. [CrossRef] [PubMed]
25. Rossi, S.L.; Fayzulin, R.; Dewsbury, N.; Bourne, N.; Mason, P.W. Mutations in West Nile virus nonstructural
proteins that facilitate replicon persistence in vitro attenuate virus replication in vitro and in vivo. Virology
2007, 364, 184–195. [CrossRef] [PubMed]
26. Audsley, M.; Edmonds, J.; Liu, W.; Mokhonov, V.; Mokhonova, E.; Melian, E.B.; Prow, N.; Hall, R.A.;
Khromykh, A.A. Virulence determinants between New York 99 and Kunjin strains of West Nile virus.
Virology 2011, 414, 63–73. [CrossRef] [PubMed]
27. Donadieu, E.; Bahuon, C.; Lowenski, S.; Zientara, S.; Coulpier, M.; Lecollinet, S. Differential virulence and
pathogenesis of West Nile viruses. Viruses 2013, 5, 2856–2880. [CrossRef] [PubMed]
28. Chambers, T.J.; Droll, D.A.; Walton, A.H.; Schwartz, J.; Wold, W.S.; Nickells, J. West Nile 25A virus infection
of B-cell-deficient ((micro)MT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral
envelope protein. J. Gen. Virol. 2008, 89, (Pt 3). 627–635. [CrossRef] [PubMed]
29. Wicker, J.A.; Whiteman, M.C.; Beasley, D.W.; Davis, C.T.; Zhang, S.; Schneider, B.S.; Higgs, S.; Kinney, R.M.;
Barrett, A.D. A single amino acid substitution in the central portion of the West Nile virus NS4B protein
confers a highly attenuated phenotype in mice. Virology 2006, 349, 245–253. [CrossRef] [PubMed]
30. Puig-Basagoiti, F.; Tilgner, M.; Bennett, C.J.; Zhou, Y.; Munoz-Jordan, J.L.; Garcia-Sastre, A.; Bernard, K.A.;
Shi, P.Y. A mouse cell-adapted NS4B mutation attenuates West Nile virus RNA synthesis. Virology 2007, 361,
229–241. [CrossRef] [PubMed]
31. Liu, W.J.; Chen, H.B.; Khromykh, A.A. Molecular and functional analyses of Kunjin virus infectious cDNA
clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3
in RNA replication. J. Virol. 2003, 77, 7804–7813. [CrossRef]
32. Leung, J.Y.; Pijlman, G.P.; Kondratieva, N.; Hyde, J.; Mackenzie, J.M.; Khromykh, A.A. Role of nonstructural
protein NS2A in flavivirus assembly. J. Virol. 2008, 82, 4731–4741. [CrossRef] [PubMed]
33. Brault, A.C.; Huang, C.Y.; Langevin, S.A.; Kinney, R.M.; Bowen, R.A.; Ramey, W.N.; Panella, N.A.;
Holmes, E.C.; Powers, A.M.; Miller, B.R. A single positively selected West Nile viral mutation confers
increased virogenesis in American crows. Nat. Genet. 2007, 39, 1162–1166. [CrossRef] [PubMed]
34. Davis, C.T.; Galbraith, S.E.; Zhang, S.; Whiteman, M.C.; Li, L.; Kinney, R.M.; Barrett, A.D. A combination of
naturally occurring mutations in North American West Nile virus nonstructural protein genes and in the 3'
untranslated region alters virus phenotype. J. Virol. 2007, 81, 6111–6116. [CrossRef] [PubMed]
35. Welte, T.; Xie, G.; Wicker, J.A.; Whiteman, M.C.; Li, L.; Rachamallu, A.; Barrett, A.; Wang, T. Immune
responses to an attenuated West Nile virus NS4B-P38G mutant strain. Vaccine 2011, 29, 4853–4861. [CrossRef]
36. Wicker, J.A.; Whiteman, M.C.; Beasley, D.W.; Davis, C.T.; McGee, C.E.; Lee, J.C.; Higgs, S.; Kinney, R.M.;
Huang, C.Y.; Barrett, A.D. Mutational analysis of the West Nile virus NS4B protein. Virology 2012, 426, 22–33.
[CrossRef] [PubMed]
37. Botha, E.M.; Markotter, W.; Wolfaardt, M.; Paweska, J.T.; Swanepoel, R.; Palacios, G.; Nel, L.H.; Venter, M.
Genetic determinants of virulence in pathogenic lineage 2 West Nile virus strains. Emerg. Infect. Dis. 2008,
14, 222–230. [CrossRef] [PubMed]
38. McMullen, A.R.; Albayrak, H.; May, F.J.; Davis, C.T.; Beasley, D.W.; Barrett, A.D. Molecular evolution of
lineage 2 West Nile virus. J. Gen. Virol. 2013, 94, (Pt 2). 318–325. [CrossRef] [PubMed]
39. Bakonyi, T.; Gould, E.A.; Kolodziejek, J.; Weissenbock, H.; Nowotny, N. Complete genome analysis and
molecular characterization of Usutu virus that emerged in Austria in 2001: comparison with the South
African strain SAAR-1776 and other flaviviruses. Virology 2004, 328, 301–310. [CrossRef] [PubMed]
40. Wang, K.; Boysen, C.; Shizuya, H.; Simon, M.I.; Hood, L. Complete nucleotide sequence of two generations
of a bacterial artificial chromosome cloning vector. Biotechniques 1997, 23, 992–994.
41. Balint, A.; Farsang, A.; Zadori, Z.; Hornyak, A.; Dencso, L.; Almazan, F.; Enjuanes, L.; Belak, S. Molecular
characterization of feline infectious peritonitis virus strain DF-2 and studies of the role of ORF3abc in viral
cell tropism. J. Virol. 2012, 86, 6258–6267. [CrossRef] [PubMed]
42. Sambrook, J.; Russell, D.W.; Fritsch, E.F.; Maniatis, T. Molecular cloning: a laboratory manual, 3rd ed.;
Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N.Y, 2001.
43. Spearman, C. The method of 'right and wrong cases' ('constant stimuli') without Gauss's formulae. Brit. J.
Psychol. 1908, 2, 227–242. [CrossRef]
Viruses 2016, 8, 49 18 of 20
44. Kärber, G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv fur Experimentelle
Pathologie und Pharmakologie 1931, 162, 480–483. [CrossRef]
45. Lim, S.M.; Koraka, P.; Osterhaus, A.D.; Martina, B.E. Development of a strand-specific real-time qRT-PCR
for the accurate detection and quantitation of West Nile virus RNA. J. Virol. Methods 2013, 194, 146–153.
[CrossRef]
46. Davis, B.S.; Chang, G.J.; Cropp, B.; Roehrig, J.T.; Martin, D.A.; Mitchell, C.J.; Bowen, R.; Bunning, M.L. West
Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro
a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol.
2001, 75, 4040–4047. [CrossRef] [PubMed]
47. Scholle, F.; Girard, Y.A.; Zhao, Q.; Higgs, S.; Mason, P.W. trans-Packaged West Nile virus-like particles:
infectious properties in vitro and in infected mosquito vectors. J. Virol. 2004, 78, 11605–11614. [CrossRef]
[PubMed]
48. Rossi, S.L.; Zhao, Q.; O'Donnell, V.K.; Mason, P.W. Adaptation of West Nile virus replicons to cells in culture
and use of replicon-bearing cells to probe antiviral action. Virology 2005, 331, 457–470. [CrossRef] [PubMed]
49. Yamshchikov, V.F.; Wengler, G.; Perelygin, A.A.; Brinton, M.A.; Compans, R.W. An infectious clone of the
West Nile flavivirus. Virology 2001, 281, 294–304. [CrossRef] [PubMed]
50. Shi, P.Y.; Tilgner, M.; Lo, M.K.; Kent, K.A.; Bernard, K.A. Infectious cDNA clone of the epidemic west nile
virus from New York City. J. Virol. 2002, 76, 5847–5856. [CrossRef]
51. Maeda, J.; Takagi, H.; Hashimoto, S.; Kurane, I.; Maeda, A. A PCR-based protocol for generating West Nile
virus replicons. J. Virol. Methods 2008, 148, 244–252. [CrossRef]
52. McGee, C.E.; Shustov, A.V.; Tsetsarkin, K.; Frolov, I.V.; Mason, P.W.; Vanlandingham, D.L.; Higgs, S. Infection,
dissemination, and transmission of a West Nile virus green fluorescent protein infectious clone by Culex
pipiens quinquefasciatus mosquitoes. Vector Borne Zoonotic Dis. 2010, 10, 267–274. [CrossRef] [PubMed]
53. Campbell, M.S.; Pletnev, A.G. Infectious cDNA clones of Langat tick-borne flavivirus that differ from their
parent in peripheral neurovirulence. Virology 2000, 269, 225–237. [CrossRef] [PubMed]
54. Montigny, C.; Penin, F.; Lethias, C.; Falson, P. Overcoming the toxicity of membrane peptide expression in
bacteria by upstream insertion of Asp-Pro sequence. Biochim. Biophys. Acta. 2004, 1660, 53–65. [CrossRef]
[PubMed]
55. Ulper, L.; Sarand, I.; Rausalu, K.; Merits, A. Construction, properties, and potential application of infectious
plasmids containing Semliki Forest virus full-length cDNA with an inserted intron. J. Virol. Methods 2008,
148, 265–270. [CrossRef]
56. Maeda, A.; Murata, R.; Akiyama, M.; Takashima, I.; Kariwa, H.; Watanabe, T.; Kurane, I.; Maeda, J.
A PCR-based protocol for the generation of a recombinant West Nile virus. Virus. Res. 2009, 144, 35–43.
[CrossRef]
57. Almazan, F.; Gonzalez, J.M.; Penzes, Z.; Izeta, A.; Calvo, E.; Plana-Duran, J.; Enjuanes, L. Engineering the
largest RNA virus genome as an infectious bacterial artificial chromosome. Proc. Natl. Acad. Sci. USA 2000,
97, 5516–5521. [CrossRef]
58. Venter, M.; Swanepoel, R. West Nile virus lineage 2 as a cause of zoonotic neurological disease in humans
and horses in southern Africa. Vector Borne Zoonotic Dis. 2010, 10, 659–664. [CrossRef] [PubMed]
59. Kaufusi, P.H.; Kelley, J.F.; Yanagihara, R.; Nerurkar, V.R. Induction of endoplasmic reticulum-derived
replication-competent membrane structures by West Nile virus non-structural protein 4B. PLoS ONE 2014, 9,
e84040. [CrossRef] [PubMed]
60. Liu, W.J.; Wang, X.J.; Mokhonov, V.V.; Shi, P.Y.; Randall, R.; Khromykh, A.A. Inhibition of interferon signaling
by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2
activation by nonstructural proteins. J. Virol. 2005, 79, 1934–1942. [CrossRef] [PubMed]
61. Munoz-Jordan, J.L.; Laurent-Rolle, M.; Ashour, J.; Martinez-Sobrido, L.; Ashok, M.; Lipkin, W.I.;
Garcia-Sastre, A. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol.
2005, 79, 8004–8013. [CrossRef] [PubMed]
62. Evans, J.D.; Seeger, C. Differential effects of mutations in NS4B on West Nile virus replication and inhibition
of interferon signaling. J. Virol. 2007, 81, 11809–11816. [CrossRef] [PubMed]
Viruses 2016, 8, 49 19 of 20
63. Laurent-Rolle, M.; Boer, E.F.; Lubick, K.J.; Wolfinbarger, J.B.; Carmody, A.B.; Rockx, B.; Liu, W.; Ashour, J.;
Shupert, W.L.; Holbrook, M.R.; et al. The NS5 protein of the virulent West Nile virus NY99 strain is a potent
antagonist of type I interferon-mediated JAK-STAT signaling. J. Virol. 2010, 84, 3503–3515. [CrossRef]
[PubMed]
64. Samuel, M.A.; Diamond, M.S. Alpha/beta interferon protects against lethal West Nile virus infection by
restricting cellular tropism and enhancing neuronal survival. J. Virol. 2005, 79, 13350–13361. [CrossRef]
[PubMed]
65. Keller, B.C.; Fredericksen, B.L.; Samuel, M.A.; Mock, R.E.; Mason, P.W.; Diamond, M.S.; Gale, M., Jr.
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence.
J. Virol. 2006, 80, 9424–9434. [CrossRef] [PubMed]
66. Suthar, M.S.; Brassil, M.M.; Blahnik, G.; Gale, M., Jr. Infectious clones of novel lineage 1 and lineage 2 West
Nile virus strains WNV-TX02 and WNV-Madagascar. J. Virol. 2012, 86, 7704–7709. [CrossRef] [PubMed]
67. Winkler, G.; Randolph, V.B.; Cleaves, G.R.; Ryan, T.E.; Stollar, V. Evidence that the mature form of the
flavivirus nonstructural protein NS1 is a dimer. Virology 1988, 162, 187–196. [CrossRef]
68. Winkler, G.; Maxwell, S.E.; Ruemmler, C.; Stollar, V. Newly synthesized dengue-2 virus nonstructural protein
NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization.
Virology 1989, 171, 302–305. [CrossRef]
69. Chung, K.M.; Liszewski, M.K.; Nybakken, G.; Davis, A.E.; Townsend, R.R.; Fremont, D.H.; Atkinson, J.P.;
Diamond, M.S. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the
regulatory protein factor H. Proc. Natl. Acad. Sci. USA 2006, 103, 19111–19116. [CrossRef] [PubMed]
70. Schlesinger, J.J. Flavivirus nonstructural protein NS1: complementary surprises. Proc. Natl. Acad. Sci. USA
2006, 103, 18879–18880. [CrossRef] [PubMed]
71. Crooks, A.J.; Lee, J.M.; Easterbrook, L.M.; Timofeev, A.V.; Stephenson, J.R. The NS1 protein of tick-borne
encephalitis virus forms multimeric species upon secretion from the host cell. J. Gen. Virol. 1994, 75, (Pt 12).
3453–3460. [CrossRef] [PubMed]
72. Flamand, M.; Megret, F.; Mathieu, M.; Lepault, J.; Rey, F.A.; Deubel, V. Dengue virus type 1 nonstructural
glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent
fashion. J. Virol. 1999, 73, 6104–6110.
73. Hall, R.A.; Khromykh, A.A.; Mackenzie, J.M.; Scherret, J.H.; Khromykh, T.I.; Mackenzie, J.S. Loss of
dimerisation of the nonstructural protein NS1 of Kunjin virus delays viral replication and reduces virulence
in mice, but still allows secretion of NS1. Virology 1999, 264, 66–75. [CrossRef] [PubMed]
74. Youn, S.; Ambrose, R.L.; Mackenzie, J.M.; Diamond, M.S. Non-structural protein-1 is required for West Nile
virus replication complex formation and viral RNA synthesis. Virol. J. 2013, 10, 339. [CrossRef] [PubMed]
75. Lindenbach, B.D.; Murray, C.L.; Thiel, H.-J.; Rice, C.M. Flaviviridae: The viruses and their replication. In
Fields Virology, 6th ed.; Knipe, D.M., Howley, P.M., Griffin, D.E., Hartin, M.A., Lamb, R.A., Roizman, B.,
Straus, S.E., Eds.; Lippincott Williams & Wilkins: New York, NY, 2013.
76. Liu, W.J.; Chen, H.B.; Wang, X.J.; Huang, H.; Khromykh, A.A. Analysis of adaptive mutations in Kunjin
virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta
interferon promoter-driven transcription. J. Virol. 2004, 78, 12225–12235. [CrossRef] [PubMed]
77. Wengler, G.; Wengler, G. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be
isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology
1991, 184, 707–715. [CrossRef]
78. Padmanabhan, R.; Mueller, N.; Reichert, E.; Yon, C.; Teramoto, T.; Kono, Y.; Takhampunya, R.; Ubol, S.;
Pattabiraman, N.; Falgout, B.; et al. Multiple enzyme activities of flavivirus proteins. Novartis Found. Symp.
2006, 277, 74–84; discussion 84–86, 251–253. [PubMed]
79. Kummerer, B.M.; Rice, C.M. Mutations in the yellow fever virus nonstructural protein NS2A selectively
block production of infectious particles. J. Virol. 2002, 76, 4773–4784. [CrossRef]
80. Langevin, S.A.; Bowen, R.A.; Reisen, W.K.; Andrade, C.C.; Ramey, W.N.; Maharaj, P.D.; Anishchenko, M.;
Kenney, J.L.; Duggal, N.K.; Romo, H.; et al. Host competence and helicase activity differences exhibited
by West Nile viral variants expressing NS3-249 amino acid polymorphisms. PLoS ONE 2014, 9, e100802.
[CrossRef] [PubMed]
81. Davis, C.T.; Beasley, D.W.; Guzman, H.; Siirin, M.; Parsons, R.E.; Tesh, R.B.; Barrett, A.D. Emergence of
attenuated West Nile virus variants in Texas, 2003. Virology 2004, 330, 342–350. [CrossRef] [PubMed]
Viruses 2016, 8, 49 20 of 20
82. Lanciotti, R.S.; Ebel, G.D.; Deubel, V.; Kerst, A.J.; Murri, S.; Meyer, R.; Bowen, M.; McKinney, N.; Morrill, W.E.;
Crabtree, M.B.; et al. Complete genome sequences and phylogenetic analysis of West Nile virus strains
isolated from the United States, Europe, and the Middle East. Virology 2002, 298, 96–105. [CrossRef]
83. Kolodziejek, J.; Marinov, M.; Kiss, B.J.; Alexe, V.; Nowotny, N. The complete sequence of a West Nile virus
lineage 2 strain detected in a Hyalomma marginatum marginatum tick collected from a song thrush (Turdus
philomelos) in eastern Romania in 2013 revealed closest genetic relationship to strain Volgograd 2007.
PLoS ONE 2014, 9, e109905. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons by Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
